Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma

Metastatic uveal melanoma (MUM) is a highly aggressive, therapy-resistant disease. Driver mutations in Gα-proteins GNAQ and GNA11 activate MAP-kinase and YAP/TAZ pathways of oncogenic signalling. MAP-kinase and MEK-inhibitors do not significantly block MUM progression, likely due to persisting YAP/T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-01, Vol.15 (3), p.886
Hauptverfasser:	Amaro, Adriana Agnese, Gangemi, Rosaria, Emionite, Laura, Castagnola, Patrizio, Filaci, Gilberto, Jager, Martine J, Tanda, Enrica Teresa, Spagnolo, Francesco, Mascherini, Matteo, Pfeffer, Ulrich, Croce, Michela
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids AKT protein Analysis Apoptosis Cancer Cancer therapies Care and treatment Cell cycle Cell lines Cerivastatin Chromosome 3 Divalproex Drug delivery Drug synergism Drug therapy Evaluation Eye cancer Gene expression Genetic aspects Guanine nucleotide-binding protein Kinases MAP kinase MEK inhibitors Melanoma Metabolism Metastases Metastasis Mevalonate pathway Monosomy Mutation Patient outcomes Phosphorylation Proteins Signal transduction Statins Transcription factors Valproic acid Verteporfin Vorinostat Yes-associated protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!